The drug developer has confidentially filed for an IPO having collected $124m in funding from investors including PureTech Health, Nan Fung and Alexandria Real Estate Equities.
Karuna Therapeutics, the US-based neuropsychiatric disorder drug developer backed by pharmaceutical firm PureTech Health and property developer Nan Fung, has confidentially filed for its initial public offering.
Founded in 2009, Karuna is developing therapies for neuropsychiatric conditions: mental disorders that are typically attributed to diseases that originate from the nervous system, such as Alzheimer’s disease-related psychosis.
The company’s lead drug candidate, KarXt, is undergoing phase 2 clinical trials for the treatment of acute psychosis in schizophrenia patients.
The news comes…
